DRUGS FOR NEGLECTED DISEASES INITIATIVE
- Country
- 🇧🇷Brazil
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.dndi.org
Clinical Trials
18
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
News
AN2 Therapeutics Partners with DNDi to Advance Oral Chagas Disease Treatment AN2-502998
AN2 Therapeutics and DNDi announced a collaboration to advance clinical development of AN2-502998, an oral drug candidate with curative potential for chronic Chagas disease affecting 6-7 million people worldwide.
Nobel Peace Prize Laureate James Orbinski Joins AI Drug Repurposing Startup Fifty 1 Labs
Dr. James Orbinski, who received the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières, has joined Fifty 1 Labs as Senior Scientist to advance AI-driven drug repurposing initiatives.
Serum Institute of India Partners with DNDi to Develop Affordable Dengue Monoclonal Antibody Treatment
Serum Institute of India and DNDi have signed an MoU to co-develop a monoclonal antibody treatment for dengue that targets all four virus serotypes, focusing on affordability for low- and middle-income countries.
First Oral Treatment for Deadly Rhodesiense Sleeping Sickness Now Available in Three African Countries
Fexinidazole Winthrop, the first all-oral treatment for Trypanosoma brucei rhodesiense sleeping sickness, is now available free of charge in Ethiopia, Malawi, and Zimbabwe.
Liverpool Researchers Trial Oral Treatment for Deadly Leishmaniasis Disease
A groundbreaking clinical trial for visceral leishmaniasis is underway in Liverpool, testing an oral drug (DNDi-6899) that could replace current painful injection treatments requiring hospitalization.
New Sustained-Release Flucytosine Enters Phase II Trials for Cryptococcal Meningitis Amid HIV Funding Crisis
A new sustained-release formulation of flucytosine for cryptococcal meningitis has entered Phase II trials in Malawi and Tanzania, simplifying dosing from four times to twice daily and improving administration options.